img

Global and United States Anti-Nuclear Radiation Drug Market Report & Forecast 2024-2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global and United States Anti-Nuclear Radiation Drug Market Report & Forecast 2024-2034

Nuclear radiation refers to the various microscopic particles and electromagnetic radiation or energy released during nuclear reactions such as fission and decay of atomic nuclei. This kind of radioactive material exists in large quantities in nuclear explosions, nuclear leakage accidents and nuclear waste. Anti-nuclear radiation drugs commonly used in clinical practice include thiol drugs, cytokine drugs, hormone drugs, metal complexing agents, and Chinese herbal medicines.
Market Analysis and InsightsGlobal and United States Anti-Nuclear Radiation Drug Market
This report focuses on global and United States Anti-Nuclear Radiation Drug market, also covers the segmentation data of other regions in regional level and county level.
The global Anti-Nuclear Radiation Drug revenue was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2029 with a CAGR of % during the forecast period (2024-2034).
The development prospect of anti-nuclear radiation medicine depends to a large extent on the development trend of global nuclear energy. If the global nuclear power generation continues to increase, the market demand for nuclear radiation protection drugs may increase accordingly.
At present, the global anti-nuclear radiation drug market has been researched and developed by some major pharmaceutical companies and biotechnology companies. The main types of anti-nuclear radiation drugs include stable iodine, Prussian blue, zinc lozenges, complement activators, antibiotics, anti-radiation drugs, etc. Among them, stable iodine and Prussian blue are the most commonly used drugs for the prevention and treatment of acute radiation exposure.
Although the market size of nuclear radiation protection drugs is relatively small, it is expected to maintain rapid growth in the coming years. This is primarily attributable to heightened concern over nuclear radiation incidents and increased need for prevention and treatment of radiation exposure.
However, the development and application of anti-nuclear radiation drugs still face some challenges. For example, anti-nuclear radiation drugs currently on the market are mainly aimed at a specific type or dose of radiation, rather than being widely applicable. In addition, due to the rarity of nuclear radiation incidents, there are certain difficulties in clinical trials and applications of these drugs.
In general, the development prospects of anti-nuclear radiation drugs seem bright, but continued in-depth research and development are needed to overcome existing technical and market challenges.
Global Anti-Nuclear Radiation Drug Scope and Market Size
Anti-Nuclear Radiation Drug market is segmented in regional and country, by players, by type and by sales channel. Companies, stakeholders, and other participants in the global Anti-Nuclear Radiation Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by sales channel for the period 2018-2029.
For United States market, this report focuses on the Anti-Nuclear Radiation Drug market size by players, by Type and by Sales Channel, for the period 2018-2029. The key players include the global and local players, which play important roles in United States.



By Company


Amgen
Humanwell Healthcare
Jiangsu Wuzhong Pharmaceutical Group
Hisun Pharmaceutical
Beijing Centergate Technologies
Lisheng Pharmaceutical
Bayer AG
GlaxoSmithKline
Pfizer
Onconova
Novartis AG
Teva Pharmaceuticals
Clinigen
Sun Pharmaceutical
Taj Pharmaceuticals
Merro Pharmaceutical
Luye Pharma
Mingren Pharma
Gilead Sciences
Johnson & Johnson
Merck KGaA
Genentech Inc.
Segment by Type
Potassium Iodide (KI)
Prussian Blue
Diethylenetriamine Pentaacetate (DTPA)
Filgrastim
Amifostine
Ex-Rad
Segment by Sales Channel
Online Sales
Offline Sales
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa

Chapter Introduction


Chapter 1Introduces Anti-Nuclear Radiation Drug definition, global sales (volume and revenue), United States market size, United States percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by sales channel, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Anti-Nuclear Radiation Drug companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Revenue and volume of Anti-Nuclear Radiation Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 6Americas by type, by sales channel and by country, sales, and revenue for each segment.
Chapter 7EMEA by type, by sales channel and by region, sales, and revenue for each segment.
Chapter 8China by type, by sales channel, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by type, by sales channel and by region, sales, and revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anti-Nuclear Radiation Drug sales, revenue, gross margin, and recent development, etc.
Chapter 11Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 12Research findings and conclusion

Table of Content

1 Study Coverage
1.1 Anti-Nuclear Radiation Drug Product Introduction
1.2 Global Anti-Nuclear Radiation Drug Outlook 2018 VS 2022 VS 2029
1.2.1 Global Anti-Nuclear Radiation Drug Sales in US$ Million for the Year 2018-2029
1.2.2 Global Anti-Nuclear Radiation Drug Sales in Volume for the Year 2018-2029
1.3 United States Anti-Nuclear Radiation Drug Outlook 2018 VS 2022 VS 2029
1.3.1 United States Anti-Nuclear Radiation Drug Sales in US$ Million for the Year 2018-2029
1.3.2 United States Anti-Nuclear Radiation Drug Sales in Volume for the Year 2018-2029
1.4 Anti-Nuclear Radiation Drug Market Size, United States VS Global, 2018 VS 2022 VS 2029
1.4.1 The Market Share of United States Anti-Nuclear Radiation Drug in Global, 2018 VS 2022 VS 2029
1.4.2 The Growth Rate of Anti-Nuclear Radiation Drug Market Size, United States VS Global, 2018 VS 2022 VS 2029
1.5 Anti-Nuclear Radiation Drug Market Dynamics
1.5.1 Anti-Nuclear Radiation Drug Industry Trends
1.5.2 Anti-Nuclear Radiation Drug Market Drivers
1.5.3 Anti-Nuclear Radiation Drug Market Challenges
1.5.4 Anti-Nuclear Radiation Drug Market Restraints
1.6 Study Objectives
1.7 Years Considered
1.8 Years Considered
2 Anti-Nuclear Radiation Drug by Type
2.1 Anti-Nuclear Radiation Drug Market Segment by Type
2.1.1 Potassium Iodide (KI)
2.1.2 Prussian Blue
2.1.3 Diethylenetriamine Pentaacetate (DTPA)
2.1.4 Filgrastim
2.1.5 Amifostine
2.1.6 Ex-Rad
2.2 Global Anti-Nuclear Radiation Drug Market Size by Type
2.2.1 Global Anti-Nuclear Radiation Drug Sales in Value, by Type (2018, 2022 & 2029)
2.2.2 Global Anti-Nuclear Radiation Drug Sales in Volume, by Type (2018, 2022 & 2029)
2.2.3 Global Anti-Nuclear Radiation Drug Average Selling Price (ASP) by Type (2018, 2022 & 2029)
2.3 United States Anti-Nuclear Radiation Drug Market Size by Type
2.3.1 United States Anti-Nuclear Radiation Drug Sales in Value, by Type (2018, 2022 & 2029)
2.3.2 United States Anti-Nuclear Radiation Drug Sales in Volume, by Type (2018, 2022 & 2029)
2.3.3 United States Anti-Nuclear Radiation Drug Average Selling Price (ASP) by Type (2018, 2022 & 2029)
3 Anti-Nuclear Radiation Drug by Sales Channel
3.1 Anti-Nuclear Radiation Drug Market Segment by Sales Channel
3.1.1 Online Sales
3.1.2 Offline Sales
3.2 Global Anti-Nuclear Radiation Drug Market Size by Sales Channel
3.2.1 Global Anti-Nuclear Radiation Drug Sales in Value, by Sales Channel (2018, 2022 & 2029)
3.2.2 Global Anti-Nuclear Radiation Drug Sales in Volume, by Sales Channel (2018, 2022 & 2029)
3.3.3 Global Anti-Nuclear Radiation Drug Average Selling Price (ASP) by Sales Channel (2018, 2022 & 2029)
3.3 United States Anti-Nuclear Radiation Drug Market Size by Sales Channel
3.3.1 United States Anti-Nuclear Radiation Drug Sales in Value, by Sales Channel (2018, 2022 & 2029)
3.3.2 United States Anti-Nuclear Radiation Drug Sales in Volume, by Sales Channel (2018, 2022 & 2029)
3.3.3 United States Anti-Nuclear Radiation Drug Average Selling Price (ASP) by Sales Channel (2018, 2022 & 2029)
4 Global Anti-Nuclear Radiation Drug Competitor Landscape by Company
4.1 Global Anti-Nuclear Radiation Drug Market Size by Company
4.1.1 Global Key Manufacturers of Anti-Nuclear Radiation Drug, Ranked by Revenue (2022)
4.1.2 Global Anti-Nuclear Radiation Drug Revenue by Manufacturer (2018-2024)
4.1.3 Global Anti-Nuclear Radiation Drug Sales by Manufacturer (2018-2024)
4.1.4 Global Anti-Nuclear Radiation Drug Price by Manufacturer (2018-2024)
4.2 Global Anti-Nuclear Radiation Drug Concentration Ratio (CR)
4.2.1 Anti-Nuclear Radiation Drug Market Concentration Ratio (CR)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Anti-Nuclear Radiation Drug in 2022
4.2.3 Global Anti-Nuclear Radiation Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Key Manufacturers of Anti-Nuclear Radiation Drug, Manufacturing Base Distribution and Headquarters
4.4 Global Key Manufacturers of Anti-Nuclear Radiation Drug, Product Offered and Application
4.5 Global Key Manufacturers of Anti-Nuclear Radiation Drug, Date of Enter into This Industry
4.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4.7 United States Anti-Nuclear Radiation Drug Market Size by Company
4.7.1 Key Players of Anti-Nuclear Radiation Drug in United States, Ranked by Revenue (2022)
4.7.2 United States Anti-Nuclear Radiation Drug Revenue by Players (2018-2024)
4.7.3 United States Anti-Nuclear Radiation Drug Sales by Players (2018-2024)
5 Global Anti-Nuclear Radiation Drug Market Size by Region
5.1 Global Anti-Nuclear Radiation Drug Market Size by Region: 2018 VS 2022 VS 2029
5.2 Global Anti-Nuclear Radiation Drug Market Size in Volume by Region (2018-2029)
5.2.1 Global Anti-Nuclear Radiation Drug Sales in Volume by Region: 2018-2024
5.2.2 Global Anti-Nuclear Radiation Drug Sales in Volume Forecast by Region (2024-2029)
5.3 Global Anti-Nuclear Radiation Drug Market Size in Value by Region (2018-2029)
5.3.1 Global Anti-Nuclear Radiation Drug Sales in Value by Region: 2018-2024
5.3.2 Global Anti-Nuclear Radiation Drug Sales in Value by Region: 2024-2029
6 Americas
6.1 Americas Anti-Nuclear Radiation Drug Market Size YoY Growth 2018-2029
6.2 Americas Anti-Nuclear Radiation Drug Sales in Volume, by Type (2018, 2022 & 2029)
6.3 Americas Anti-Nuclear Radiation Drug Sales in Volume, by Sales Channel (2018, 2022 & 2029)
6.4 Americas Anti-Nuclear Radiation Drug Market Facts & Figures by Country (2018, 2022 & 2029)
6.4.1 Americas Anti-Nuclear Radiation Drug Sales in Value by Country (2018, 2022 & 2029)
6.4.2 Americas Anti-Nuclear Radiation Drug Sales in Volume by Country (2018, 2022 & 2029)
6.4.3 United States
6.4.4 Canada
6.4.5 Mexico
6.4.6 Brazil
7 EMEA
7.1 EMEA Anti-Nuclear Radiation Drug Market Size YoY Growth 2018-2029
7.2 EMEA Anti-Nuclear Radiation Drug Sales in Volume, by Type (2018, 2022 & 2029)
7.3 EMEA Anti-Nuclear Radiation Drug Sales in Volume, by Sales Channel (2018, 2022 & 2029)
7.4 EMEA Anti-Nuclear Radiation Drug Market Facts & Figures by Country (2018, 2022 & 2029)
7.4.1 EMEA Anti-Nuclear Radiation Drug Sales in Value by Country (2018, 2022 & 2029)
7.4.2 EMEA Anti-Nuclear Radiation Drug Sales in Volume by Country (2018, 2022 & 2029)
7.4.3 Europe
7.4.4 Middle East
7.4.5 Africa
8 China
8.1 China Anti-Nuclear Radiation Drug Market Size YoY Growth 2018-2029
8.2 China Anti-Nuclear Radiation Drug Sales in Volume, by Type (2018, 2022 & 2029)
8.3 China Anti-Nuclear Radiation Drug Sales in Volume, by Sales Channel (2018, 2022 & 2029)
9 APAC
9.1 APAC Anti-Nuclear Radiation Drug Market Size YoY Growth 2018-2029
9.2 APAC Anti-Nuclear Radiation Drug Sales in Volume, by Type (2018, 2022 & 2029)
9.3 APAC Anti-Nuclear Radiation Drug Sales in Volume, by Sales Channel (2018, 2022 & 2029)
9.4 APAC Anti-Nuclear Radiation Drug Market Facts & Figures by Region (2018, 2022 & 2029)
9.4.1 APAC Anti-Nuclear Radiation Drug Sales in Value by Region (2018, 2022 & 2029)
9.4.2 APAC Anti-Nuclear Radiation Drug Sales in Volume by Region (2018, 2022 & 2029)
9.4.3 Japan
9.4.4 South Korea
9.4.5 China Taiwan
9.4.6 Southeast Asia
9.4.7 India
10 Company Profiles
10.1 Amgen
10.1.1 Amgen Company Information
10.1.2 Amgen Description and Business Overview
10.1.3 Amgen Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
10.1.4 Amgen Anti-Nuclear Radiation Drug Products Offered
10.1.5 Amgen Recent Development
10.2 Humanwell Healthcare
10.2.1 Humanwell Healthcare Company Information
10.2.2 Humanwell Healthcare Description and Business Overview
10.2.3 Humanwell Healthcare Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
10.2.4 Humanwell Healthcare Anti-Nuclear Radiation Drug Products Offered
10.2.5 Humanwell Healthcare Recent Development
10.3 Jiangsu Wuzhong Pharmaceutical Group
10.3.1 Jiangsu Wuzhong Pharmaceutical Group Company Information
10.3.2 Jiangsu Wuzhong Pharmaceutical Group Description and Business Overview
10.3.3 Jiangsu Wuzhong Pharmaceutical Group Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
10.3.4 Jiangsu Wuzhong Pharmaceutical Group Anti-Nuclear Radiation Drug Products Offered
10.3.5 Jiangsu Wuzhong Pharmaceutical Group Recent Development
10.4 Hisun Pharmaceutical
10.4.1 Hisun Pharmaceutical Company Information
10.4.2 Hisun Pharmaceutical Description and Business Overview
10.4.3 Hisun Pharmaceutical Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
10.4.4 Hisun Pharmaceutical Anti-Nuclear Radiation Drug Products Offered
10.4.5 Hisun Pharmaceutical Recent Development
10.5 Beijing Centergate Technologies
10.5.1 Beijing Centergate Technologies Company Information
10.5.2 Beijing Centergate Technologies Description and Business Overview
10.5.3 Beijing Centergate Technologies Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
10.5.4 Beijing Centergate Technologies Anti-Nuclear Radiation Drug Products Offered
10.5.5 Beijing Centergate Technologies Recent Development
10.6 Lisheng Pharmaceutical
10.6.1 Lisheng Pharmaceutical Company Information
10.6.2 Lisheng Pharmaceutical Description and Business Overview
10.6.3 Lisheng Pharmaceutical Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
10.6.4 Lisheng Pharmaceutical Anti-Nuclear Radiation Drug Products Offered
10.6.5 Lisheng Pharmaceutical Recent Development
10.7 Bayer AG
10.7.1 Bayer AG Company Information
10.7.2 Bayer AG Description and Business Overview
10.7.3 Bayer AG Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
10.7.4 Bayer AG Anti-Nuclear Radiation Drug Products Offered
10.7.5 Bayer AG Recent Development
10.8 GlaxoSmithKline
10.8.1 GlaxoSmithKline Company Information
10.8.2 GlaxoSmithKline Description and Business Overview
10.8.3 GlaxoSmithKline Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
10.8.4 GlaxoSmithKline Anti-Nuclear Radiation Drug Products Offered
10.8.5 GlaxoSmithKline Recent Development
10.9 Pfizer
10.9.1 Pfizer Company Information
10.9.2 Pfizer Description and Business Overview
10.9.3 Pfizer Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
10.9.4 Pfizer Anti-Nuclear Radiation Drug Products Offered
10.9.5 Pfizer Recent Development
10.10 Onconova
10.10.1 Onconova Company Information
10.10.2 Onconova Description and Business Overview
10.10.3 Onconova Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
10.10.4 Onconova Anti-Nuclear Radiation Drug Products Offered
10.10.5 Onconova Recent Development
10.11 Novartis AG
10.11.1 Novartis AG Company Information
10.11.2 Novartis AG Description and Business Overview
10.11.3 Novartis AG Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
10.11.4 Novartis AG Anti-Nuclear Radiation Drug Products Offered
10.11.5 Novartis AG Recent Development
10.12 Teva Pharmaceuticals
10.12.1 Teva Pharmaceuticals Company Information
10.12.2 Teva Pharmaceuticals Description and Business Overview
10.12.3 Teva Pharmaceuticals Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
10.12.4 Teva Pharmaceuticals Anti-Nuclear Radiation Drug Products Offered
10.12.5 Teva Pharmaceuticals Recent Development
10.13 Clinigen
10.13.1 Clinigen Company Information
10.13.2 Clinigen Description and Business Overview
10.13.3 Clinigen Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
10.13.4 Clinigen Anti-Nuclear Radiation Drug Products Offered
10.13.5 Clinigen Recent Development
10.14 Sun Pharmaceutical
10.14.1 Sun Pharmaceutical Company Information
10.14.2 Sun Pharmaceutical Description and Business Overview
10.14.3 Sun Pharmaceutical Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
10.14.4 Sun Pharmaceutical Anti-Nuclear Radiation Drug Products Offered
10.14.5 Sun Pharmaceutical Recent Development
10.15 Taj Pharmaceuticals
10.15.1 Taj Pharmaceuticals Company Information
10.15.2 Taj Pharmaceuticals Description and Business Overview
10.15.3 Taj Pharmaceuticals Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
10.15.4 Taj Pharmaceuticals Anti-Nuclear Radiation Drug Products Offered
10.15.5 Taj Pharmaceuticals Recent Development
10.16 Merro Pharmaceutical
10.16.1 Merro Pharmaceutical Company Information
10.16.2 Merro Pharmaceutical Description and Business Overview
10.16.3 Merro Pharmaceutical Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
10.16.4 Merro Pharmaceutical Anti-Nuclear Radiation Drug Products Offered
10.16.5 Merro Pharmaceutical Recent Development
10.17 Luye Pharma
10.17.1 Luye Pharma Company Information
10.17.2 Luye Pharma Description and Business Overview
10.17.3 Luye Pharma Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
10.17.4 Luye Pharma Anti-Nuclear Radiation Drug Products Offered
10.17.5 Luye Pharma Recent Development
10.18 Mingren Pharma
10.18.1 Mingren Pharma Company Information
10.18.2 Mingren Pharma Description and Business Overview
10.18.3 Mingren Pharma Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
10.18.4 Mingren Pharma Anti-Nuclear Radiation Drug Products Offered
10.18.5 Mingren Pharma Recent Development
10.19 Gilead Sciences
10.19.1 Gilead Sciences Company Information
10.19.2 Gilead Sciences Description and Business Overview
10.19.3 Gilead Sciences Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
10.19.4 Gilead Sciences Anti-Nuclear Radiation Drug Products Offered
10.19.5 Gilead Sciences Recent Development
10.20 Johnson & Johnson
10.20.1 Johnson & Johnson Company Information
10.20.2 Johnson & Johnson Description and Business Overview
10.20.3 Johnson & Johnson Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
10.20.4 Johnson & Johnson Anti-Nuclear Radiation Drug Products Offered
10.20.5 Johnson & Johnson Recent Development
10.21 Merck KGaA
10.21.1 Merck KGaA Company Information
10.21.2 Merck KGaA Description and Business Overview
10.21.3 Merck KGaA Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
10.21.4 Merck KGaA Anti-Nuclear Radiation Drug Products Offered
10.21.5 Merck KGaA Recent Development
10.22 Genentech Inc.
10.22.1 Genentech Inc. Company Information
10.22.2 Genentech Inc. Description and Business Overview
10.22.3 Genentech Inc. Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2024)
10.22.4 Genentech Inc. Anti-Nuclear Radiation Drug Products Offered
10.22.5 Genentech Inc. Recent Development
11 Industry Chain and Sales Channels Analysis
11.1 Anti-Nuclear Radiation Drug Industry Chain Analysis
11.2 Anti-Nuclear Radiation Drug Key Raw Materials
11.2.1 Key Raw Materials
11.2.2 Raw Materials Key Suppliers
11.3 Anti-Nuclear Radiation Drug Production Mode & Process
11.4 Anti-Nuclear Radiation Drug Sales and Marketing
11.4.1 Anti-Nuclear Radiation Drug Sales Channels
11.4.2 Anti-Nuclear Radiation Drug Distributors
11.5 Anti-Nuclear Radiation Drug Customers
12 Research Findings and Conclusion
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

List of Figure

List of Tables
Table 1. Anti-Nuclear Radiation Drug CAGR in Value, United States VS Global, 2018 VS 2022 VS 2029
Table 2. Anti-Nuclear Radiation Drug Market Trends
Table 3. Anti-Nuclear Radiation Drug Market Drivers
Table 4. Anti-Nuclear Radiation Drug Market Challenges
Table 5. Anti-Nuclear Radiation Drug Market Restraints
Table 6. Global Anti-Nuclear Radiation Drug Sales Growth Rate (CAGR) by Type: 2018 VS 2022 VS 2029 (US$ Million)
Table 7. United States Anti-Nuclear Radiation Drug Sales Growth Rate (CAGR) by Type: 2018 VS 2022 VS 2029 (US$ Million)
Table 8. Global Anti-Nuclear Radiation Drug Sales Growth Rate (CAGR) by Sales Channel: 2018 VS 2022 VS 2029 (US$ Million)
Table 9. United States Anti-Nuclear Radiation Drug Sales Growth Rate (CAGR) by Sales Channel: 2018 VS 2022 VS 2029 (US$ Million)
Table 10. Global Key Manufacturers of Anti-Nuclear Radiation Drug, Ranked by Revenue (2022) & (US$ Million)
Table 11. Global Anti-Nuclear Radiation Drug Revenue by Manufacturer, (US$ Million), 2018-2024
Table 12. Global Anti-Nuclear Radiation Drug Revenue Share by Manufacturer, 2018-2024
Table 13. Global Anti-Nuclear Radiation Drug Sales by Manufacturer, (K Units), 2018-2024
Table 14. Global Anti-Nuclear Radiation Drug Sales Share by Manufacturer, 2018-2024
Table 15. Global Anti-Nuclear Radiation Drug Price by Manufacturer (2018-2024) & (US$/Unit)
Table 16. Global Anti-Nuclear Radiation Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 17. Global Anti-Nuclear Radiation Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-Nuclear Radiation Drug as of 2022)
Table 18. Global Key Manufacturers of Anti-Nuclear Radiation Drug, Manufacturing Base Distribution and Headquarters
Table 19. Global Key Manufacturers of Anti-Nuclear Radiation Drug, Product Offered and Application
Table 20. Global Key Manufacturers of Anti-Nuclear Radiation Drug, Date of Enter into This Industry
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Key Players of Anti-Nuclear Radiation Drug in United States, Ranked by Revenue (2022) & (US$ million)
Table 23. United States Anti-Nuclear Radiation Drug Revenue by Players, (US$ Million), (2018-2024)
Table 24. United States Anti-Nuclear Radiation Drug Revenue Share by Players, (2018-2024)
Table 25. United States Anti-Nuclear Radiation Drug Sales by Players, (K Units), (2018-2024)
Table 26. United States Anti-Nuclear Radiation Drug Sales Share by Players, (2018-2024)
Table 27. Global Anti-Nuclear Radiation Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 28. Global Anti-Nuclear Radiation Drug Sales in Volume by Region (2018-2024) & (K Units)
Table 29. Global Anti-Nuclear Radiation Drug Sales in Volume Forecast by Region (2024-2029) & (K Units)
Table 30. Global Anti-Nuclear Radiation Drug Sales in Value by Region (2018-2024) & (US$ Million)
Table 31. Global Anti-Nuclear Radiation Drug Sales in Value Forecast by Region (2024-2029) & (US$ Million)
Table 32. Americas Anti-Nuclear Radiation Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 33. Americas Anti-Nuclear Radiation Drug Sales in Value by Country (2018-2024) & (US$ Million)
Table 34. Americas Anti-Nuclear Radiation Drug Sales in Value by Country (2024-2029) & (US$ Million)
Table 35. Americas Anti-Nuclear Radiation Drug Sales in Volume by Country (2018-2024) & (K Units)
Table 36. Americas Anti-Nuclear Radiation Drug Sales in Volume by Country (2024-2029) & (K Units)
Table 37. EMEA Anti-Nuclear Radiation Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 38. EMEA Anti-Nuclear Radiation Drug Sales in Value by Country (2018-2024) & (US$ Million)
Table 39. EMEA Anti-Nuclear Radiation Drug Sales in Value by Country (2024-2029) & (US$ Million)
Table 40. EMEA Anti-Nuclear Radiation Drug Sales in Volume by Country (2018-2024) & (K Units)
Table 41. EMEA Anti-Nuclear Radiation Drug Sales in Volume by Country (2024-2029) & (K Units)
Table 42. APAC Anti-Nuclear Radiation Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 43. APAC Anti-Nuclear Radiation Drug Sales in Value by Country (2018-2024) & (US$ Million)
Table 44. APAC Anti-Nuclear Radiation Drug Sales in Value by Country (2024-2029) & (US$ Million)
Table 45. APAC Anti-Nuclear Radiation Drug Sales in Volume by Country (2018-2024) & (K Units)
Table 46. APAC Anti-Nuclear Radiation Drug Sales in Volume by Country (2024-2029) & (K Units)
Table 47. Amgen Company Information
Table 48. Amgen Description and Business Overview
Table 49. Amgen Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 50. Amgen Anti-Nuclear Radiation Drug Product
Table 51. Amgen Recent Development
Table 52. Humanwell Healthcare Company Information
Table 53. Humanwell Healthcare Description and Business Overview
Table 54. Humanwell Healthcare Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 55. Humanwell Healthcare Anti-Nuclear Radiation Drug Product
Table 56. Humanwell Healthcare Recent Development
Table 57. Jiangsu Wuzhong Pharmaceutical Group Company Information
Table 58. Jiangsu Wuzhong Pharmaceutical Group Description and Business Overview
Table 59. Jiangsu Wuzhong Pharmaceutical Group Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 60. Jiangsu Wuzhong Pharmaceutical Group Anti-Nuclear Radiation Drug Product
Table 61. Jiangsu Wuzhong Pharmaceutical Group Recent Development
Table 62. Hisun Pharmaceutical Company Information
Table 63. Hisun Pharmaceutical Description and Business Overview
Table 64. Hisun Pharmaceutical Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 65. Hisun Pharmaceutical Anti-Nuclear Radiation Drug Product
Table 66. Hisun Pharmaceutical Recent Development
Table 67. Beijing Centergate Technologies Company Information
Table 68. Beijing Centergate Technologies Description and Business Overview
Table 69. Beijing Centergate Technologies Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 70. Beijing Centergate Technologies Anti-Nuclear Radiation Drug Product
Table 71. Beijing Centergate Technologies Recent Development
Table 72. Lisheng Pharmaceutical Company Information
Table 73. Lisheng Pharmaceutical Description and Business Overview
Table 74. Lisheng Pharmaceutical Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 75. Lisheng Pharmaceutical Anti-Nuclear Radiation Drug Product
Table 76. Lisheng Pharmaceutical Recent Development
Table 77. Bayer AG Company Information
Table 78. Bayer AG Description and Business Overview
Table 79. Bayer AG Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 80. Bayer AG Anti-Nuclear Radiation Drug Product
Table 81. Bayer AG Recent Development
Table 82. GlaxoSmithKline Company Information
Table 83. GlaxoSmithKline Description and Business Overview
Table 84. GlaxoSmithKline Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 85. GlaxoSmithKline Anti-Nuclear Radiation Drug Product
Table 86. GlaxoSmithKline Recent Development
Table 87. Pfizer Company Information
Table 88. Pfizer Description and Business Overview
Table 89. Pfizer Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 90. Pfizer Anti-Nuclear Radiation Drug Product
Table 91. Pfizer Recent Development
Table 92. Onconova Company Information
Table 93. Onconova Description and Business Overview
Table 94. Onconova Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 95. Onconova Anti-Nuclear Radiation Drug Product
Table 96. Onconova Recent Development
Table 97. Novartis AG Company Information
Table 98. Novartis AG Description and Business Overview
Table 99. Novartis AG Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 100. Novartis AG Anti-Nuclear Radiation Drug Product
Table 101. Novartis AG Recent Development
Table 102. Teva Pharmaceuticals Company Information
Table 103. Teva Pharmaceuticals Description and Business Overview
Table 104. Teva Pharmaceuticals Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 105. Teva Pharmaceuticals Anti-Nuclear Radiation Drug Product
Table 106. Teva Pharmaceuticals Recent Development
Table 107. Clinigen Company Information
Table 108. Clinigen Description and Business Overview
Table 109. Clinigen Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 110. Clinigen Anti-Nuclear Radiation Drug Product
Table 111. Clinigen Recent Development
Table 112. Sun Pharmaceutical Company Information
Table 113. Sun Pharmaceutical Description and Business Overview
Table 114. Sun Pharmaceutical Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 115. Sun Pharmaceutical Anti-Nuclear Radiation Drug Product
Table 116. Sun Pharmaceutical Recent Development
Table 117. Taj Pharmaceuticals Company Information
Table 118. Taj Pharmaceuticals Description and Business Overview
Table 119. Taj Pharmaceuticals Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 120. Taj Pharmaceuticals Anti-Nuclear Radiation Drug Product
Table 121. Taj Pharmaceuticals Recent Development
Table 122. Merro Pharmaceutical Company Information
Table 123. Merro Pharmaceutical Description and Business Overview
Table 124. Merro Pharmaceutical Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 125. Merro Pharmaceutical Anti-Nuclear Radiation Drug Product
Table 126. Merro Pharmaceutical Recent Development
Table 127. Luye Pharma Company Information
Table 128. Luye Pharma Description and Business Overview
Table 129. Luye Pharma Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 130. Luye Pharma Anti-Nuclear Radiation Drug Product
Table 131. Luye Pharma Recent Development
Table 132. Mingren Pharma Company Information
Table 133. Mingren Pharma Description and Business Overview
Table 134. Mingren Pharma Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 135. Mingren Pharma Anti-Nuclear Radiation Drug Product
Table 136. Mingren Pharma Recent Development
Table 137. Gilead Sciences Company Information
Table 138. Gilead Sciences Description and Business Overview
Table 139. Gilead Sciences Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 140. Gilead Sciences Anti-Nuclear Radiation Drug Product
Table 141. Gilead Sciences Recent Development
Table 142. Johnson & Johnson Company Information
Table 143. Johnson & Johnson Description and Business Overview
Table 144. Johnson & Johnson Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 145. Johnson & Johnson Anti-Nuclear Radiation Drug Product
Table 146. Johnson & Johnson Recent Development
Table 147. Merck KGaA Company Information
Table 148. Merck KGaA Description and Business Overview
Table 149. Merck KGaA Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 150. Merck KGaA Anti-Nuclear Radiation Drug Product
Table 151. Merck KGaA Recent Development
Table 152. Genentech Inc. Company Information
Table 153. Genentech Inc. Description and Business Overview
Table 154. Genentech Inc. Anti-Nuclear Radiation Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 155. Genentech Inc. Anti-Nuclear Radiation Drug Product
Table 156. Genentech Inc. Recent Development
Table 157. Key Raw Materials Lists
Table 158. Raw Materials Key Suppliers Lists
Table 159. Anti-Nuclear Radiation Drug Customers List
Table 160. Anti-Nuclear Radiation Drug Distributors List
Table 161. Research Programs/Design for This Report
Table 162. Key Data Information from Secondary Sources
Table 163. Key Data Information from Primary Sources
List of Figures
Figure 1. Anti-Nuclear Radiation Drug Product Picture
Figure 2. Global Anti-Nuclear Radiation Drug Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 3. Global Anti-Nuclear Radiation Drug Market Size 2018-2029 (US$ Million)
Figure 4. Global Anti-Nuclear Radiation Drug Sales 2018-2029 (K Units)
Figure 5. United States Anti-Nuclear Radiation Drug Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 6. United States Anti-Nuclear Radiation Drug Market Size 2018-2029 (US$ Million)
Figure 7. United States Anti-Nuclear Radiation Drug Sales 2018-2029 (K Units)
Figure 8. United States Anti-Nuclear Radiation Drug Market Share in Global, in Value (US$ Million) 2018-2029
Figure 9. United States Anti-Nuclear Radiation Drug Market Share in Global, in Volume (K Units) 2018-2029
Figure 10. Anti-Nuclear Radiation Drug Report Years Considered
Figure 11. Product Picture of Potassium Iodide (KI)
Figure 12. Product Picture of Prussian Blue
Figure 13. Product Picture of Diethylenetriamine Pentaacetate (DTPA)
Figure 14. Product Picture of Filgrastim
Figure 15. Product Picture of Amifostine
Figure 16. Product Picture of Ex-Rad
Figure 17. Global Anti-Nuclear Radiation Drug Market Share by Type in 2022 & 2029
Figure 18. Global Anti-Nuclear Radiation Drug Sales in Value by Type (2018-2029) & (US$ Million)
Figure 19. Global Anti-Nuclear Radiation Drug Sales Market Share in Value by Type (2018-2029)
Figure 20. Global Anti-Nuclear Radiation Drug Sales by Type (2018-2029) & (K Units)
Figure 21. Global Anti-Nuclear Radiation Drug Sales Market Share in Volume by Type (2018-2029)
Figure 22. Global Anti-Nuclear Radiation Drug Price by Type (2018-2029) & (US$/Unit)
Figure 23. United States Anti-Nuclear Radiation Drug Market Share by Type in 2022 & 2029
Figure 24. United States Anti-Nuclear Radiation Drug Sales in Value by Type (2018-2029) & (US$ Million)
Figure 25. United States Anti-Nuclear Radiation Drug Sales Market Share in Value by Type (2018-2029)
Figure 26. United States Anti-Nuclear Radiation Drug Sales by Type (2018-2029) & (K Units)
Figure 27. United States Anti-Nuclear Radiation Drug Sales Market Share in Volume by Type (2018-2029)
Figure 28. United States Anti-Nuclear Radiation Drug Price by Type (2018-2029) & (US$/Unit)
Figure 29. Product Picture of Online Sales
Figure 30. Product Picture of Offline Sales
Figure 31. Global Anti-Nuclear Radiation Drug Market Share by Sales Channel in 2022 & 2029
Figure 32. Global Anti-Nuclear Radiation Drug Sales in Value by Sales Channel (2018-2029) & (US$ Million)
Figure 33. Global Anti-Nuclear Radiation Drug Sales Market Share in Value by Sales Channel (2018-2029)
Figure 34. Global Anti-Nuclear Radiation Drug Sales by Sales Channel (2018-2029) & (K Units)
Figure 35. Global Anti-Nuclear Radiation Drug Sales Market Share in Volume by Sales Channel (2018-2029)
Figure 36. Global Anti-Nuclear Radiation Drug Price by Sales Channel (2018-2029) & (US$/Unit)
Figure 37. United States Anti-Nuclear Radiation Drug Market Share by Sales Channel in 2022 & 2029
Figure 38. United States Anti-Nuclear Radiation Drug Sales in Value by Sales Channel (2018-2029) & (US$ Million)
Figure 39. United States Anti-Nuclear Radiation Drug Sales Market Share in Value by Sales Channel (2018-2029)
Figure 40. United States Anti-Nuclear Radiation Drug Sales by Sales Channel (2018-2029) & (K Units)
Figure 41. United States Anti-Nuclear Radiation Drug Sales Market Share in Volume by Sales Channel (2018-2029)
Figure 42. United States Anti-Nuclear Radiation Drug Price by Sales Channel (2018-2029) & (US$/Unit)
Figure 43. Americas Anti-Nuclear Radiation Drug Sales in Volume Growth Rate 2018-2029 (K Units)
Figure 44. Americas Anti-Nuclear Radiation Drug Sales in Value Growth Rate 2018-2029 (US$ Million)
Figure 45. Americas Anti-Nuclear Radiation Drug Sales by Type (2018-2029) & (K Units)
Figure 46. Americas Anti-Nuclear Radiation Drug Sales Market Share in Volume by Type (2018-2029)
Figure 47. Americas Anti-Nuclear Radiation Drug Sales by Sales Channel (2018-2029) & (K Units)
Figure 48. Americas Anti-Nuclear Radiation Drug Sales Market Share in Volume by Sales Channel (2018-2029)
Figure 49. United States Anti-Nuclear Radiation Drug Sales in Value Growth Rate (2018-2029) & (US$ Million)
Figure 50. Canada Anti-Nuclear Radiation Drug Sales in Value Growth Rate (2018-2029) & (US$ Million)
Figure 51. Mexico Anti-Nuclear Radiation Drug Sales in Value Growth Rate (2018-2029) & (US$ Million)
Figure 52. Brazil Anti-Nuclear Radiation Drug Sales in Value Growth Rate (2018-2029) & (US$ Million)
Figure 53. EMEA Anti-Nuclear Radiation Drug Sales in Volume Growth Rate 2018-2029 (K Units)
Figure 54. EMEA Anti-Nuclear Radiation Drug Sales in Value Growth Rate 2018-2029 (US$ Million)
Figure 55. EMEA Anti-Nuclear Radiation Drug Sales by Type (2018-2029) & (K Units)
Figure 56. EMEA Anti-Nuclear Radiation Drug Sales Market Share in Volume by Type (2018-2029)
Figure 57. EMEA Anti-Nuclear Radiation Drug Sales by Sales Channel (2018-2029) & (K Units)
Figure 58. EMEA Anti-Nuclear Radiation Drug Sales Market Share in Volume by Sales Channel (2018-2029)
Figure 59. Europe Anti-Nuclear Radiation Drug Sales in Value Growth Rate (2018-2029) & (US$ Million)
Figure 60. Middle East Anti-Nuclear Radiation Drug Sales in Value Growth Rate (2018-2029) & (US$ Million)
Figure 61. Africa Anti-Nuclear Radiation Drug Sales in Value Growth Rate (2018-2029) & (US$ Million)
Figure 62. China Anti-Nuclear Radiation Drug Sales in Volume Growth Rate 2018-2029 (K Units)
Figure 63. China Anti-Nuclear Radiation Drug Sales in Value Growth Rate 2018-2029 (US$ Million)
Figure 64. China Anti-Nuclear Radiation Drug Sales by Type (2018-2029) & (K Units)
Figure 65. China Anti-Nuclear Radiation Drug Sales Market Share in Volume by Type (2018-2029)
Figure 66. China Anti-Nuclear Radiation Drug Sales by Sales Channel (2018-2029) & (K Units)
Figure 67. China Anti-Nuclear Radiation Drug Sales Market Share in Volume by Sales Channel (2018-2029)
Figure 68. APAC Anti-Nuclear Radiation Drug Sales in Volume Growth Rate 2018-2029 (K Units)
Figure 69. APAC Anti-Nuclear Radiation Drug Sales in Value Growth Rate 2018-2029 (US$ Million)
Figure 70. APAC Anti-Nuclear Radiation Drug Sales by Type (2018-2029) & (K Units)
Figure 71. APAC Anti-Nuclear Radiation Drug Sales Market Share in Volume by Type (2018-2029)
Figure 72. APAC Anti-Nuclear Radiation Drug Sales by Sales Channel (2018-2029) & (K Units)
Figure 73. APAC Anti-Nuclear Radiation Drug Sales Market Share in Volume by Sales Channel (2018-2029)
Figure 74. Japan Anti-Nuclear Radiation Drug Sales in Value Growth Rate (2018-2029) & (US$ Million)
Figure 75. South Korea Anti-Nuclear Radiation Drug Sales in Value Growth Rate (2018-2029) & (US$ Million)
Figure 76. China Taiwan Anti-Nuclear Radiation Drug Sales in Value Growth Rate (2018-2029) & (US$ Million)
Figure 77. Southeast Asia Anti-Nuclear Radiation Drug Sales in Value Growth Rate (2018-2029) & (US$ Million)
Figure 78. India Anti-Nuclear Radiation Drug Sales in Value Growth Rate (2018-2029) & (US$ Million)
Figure 79. Anti-Nuclear Radiation Drug Value Chain
Figure 80. Anti-Nuclear Radiation Drug Production Process
Figure 81. Channels of Distribution
Figure 82. Distributors Profiles
Figure 83. Bottom-up and Top-down Approaches for This Report
Figure 84. Data Triangulation
Figure 85. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries